ライフサイエンスコーパス: glycemic control

1 ects on food intake, energy homeostasis, and glycemic control.

2 ry intake than for biomarkers of longer-term glycemic control.

3 stinal glucose absorption in vivo to improve glycemic control.

4 does not appear to be effective in improving glycemic control.

5 nts with type 2 diabetes mellitus under poor glycemic control.

6 ependent therapeutic effects on postprandial glycemic control.

7 to a weight-loss-independent improvement in glycemic control.

8 veness demonstrated therapeutically relevant glycemic control.

9 r for type 2 diabetes that adversely impacts glycemic control.

10 challenge and were associated with improved glycemic control.

11 ons in diabetic patients, despite subsequent glycemic control.

12 their capacities to lose weight and improve glycemic control.

13 stribution were associated with more optimal glycemic control.

14 ve treatments to establish and maintain good glycemic control.

15 hormone with extrapancreatic effects beyond glycemic control.

16 abetes mellitus patients under good and poor glycemic control.

17 er label and users of both labels had poorer glycemic control.

18 hout overt cardiovascular disease and stable glycemic control.

19 enewable source of functional beta cells for glycemic control.

20 e hypothalamic ventromedial nucleus (VMN) in glycemic control.

21 support the use of resveratrol for improving glycemic control.

22 titis, including self-reported DM status and glycemic control.

23 ive period but did not significantly improve glycemic control.

24 oliferation, increase islet mass and improve glycemic control.

25 on between periodontitis, diabetes (DM), and glycemic control.

26 ch as of EPA, may be important for long-term glycemic control.

27 agement, hospital readmissions, and diabetic glycemic control.

28 tor inhibitor 1 (PAI-1), regardless of their glycemic control.

29 y lipoprotein cholesterol, triglycerides, or glycemic control.

30 tential as a therapeutic strategy to improve glycemic control.

31 ic benefit was commensurate with the loss of glycemic control.

32 ediator of cognitive deficits independent of glycemic control.

33 adolescents with type 1 diabetes to improve glycemic control.

34 the control of food intake, body weight, or glycemic control.

35 bination therapy more efficiently maintained glycemic control.

36 al in insulin resistance and correlates with glycemic control.

37 emales with longer disease duration and poor glycemic control.

38 s with type 1 diabetes and various levels of glycemic control.

39 ar-daily basis for 24 weeks and had improved glycemic control.

40 Individualized versus uniform intensive glycemic control.

41 - and gender- matched counterparts with good glycemic control.

42 ay be more vulnerable to the insults of poor glycemic control.

43 tric patients with T1D after one-year's poor glycemic control.

44 al for many homeostatic processes, including glycemic control.

45 nts, but little is known about the impact of glycemic control.

46 36E4ORF1 but not Ad5E4ORF1 robustly improved glycemic control.

47 nts with type 2 diabetes, negatively affects glycemic control.

48 (vGMS) is associated with improved inpatient glycemic control.

49 ears or longer at baseline, insulin use, and glycemic control.

50 tions among T1D pediatric patients with poor glycemic control.

51 th HbA1c as a surrogate marker indicator for glycemic control.

52 abetes, is a major barrier to achieving good glycemic control.

53 n pharmacologic therapy is needed to improve glycemic control.

54 stems, including in aldosterone function and glycemic control.

55 one cardiac surgery) to one of two ranges of glycemic control: 80 to 110 mg per deciliter (4.4 to 6.1

56 tion of metformin to insulin did not improve glycemic control after 6 months.

57 y and major adverse events despite favorable glycemic control after LVAD implantation.

58 ctive effect of NR could not be explained by glycemic control alone.

59 (alphagp130KO) mice showed no differences in glycemic control, alpha-cell function, or alpha-cell mas

60 e significantly higher in patients with poor glycemic control, although the plasma levels of both pro

61 he Behavioral Economic Incentives to Improve Glycemic Control Among Adolescents and Young Adults With

62 ded in a clinical setting improved long-term glycemic control among individuals with type 2 diabetes

63 ong-term treatment of periodontal disease on glycemic control among individuals with type 2 diabetes.

64 vitamin D2 from 31 T1D patients with optimal glycemic control and 60 T1D patients with suboptimal gly

65 e 1 diabetes (T1D) and proteinuria have poor glycemic control and a high risk of ESRD.

66 e analysis revealed association between poor glycemic control and arterial hypertension, presence of

67 control and 60 T1D patients with suboptimal glycemic control and assessed their tolerogenic properti

68 at increased NAD(+) metabolism might address glycemic control and be neuroprotective, we treated pred

69 Improved glycemic control and better management of other identifi

70 th a high-carbohydrate, low-fat (HC) diet on glycemic control and cardiovascular disease risk factors

71 y during these years is associated with poor glycemic control and complications from diabetes in adul

72 groups, islet transplantation restored good glycemic control and drastically reduced hypoglycemia an

73 ansplantation, recipients were monitored for glycemic control and glucose tolerance.

74 This study demonstrates the importance of glycemic control and identifies potential therapeutic ta

75 treatment for 6 months resulted in improved glycemic control and insulin resistance compared with re

76 Recipient mice were monitored for glycemic control and intraperitoneal glucose tolerance.

77 nsplant recipients and examined the level of glycemic control and its associated factors, as well as

78 all margin between a dose that achieves good glycemic control and one that causes hypoglycemia.

79 Despite this, the current level of glycemic control and quality of screening strategies for

80 study, we assessed these risks according to glycemic control and renal complications among persons w

81 s with type 2 diabetes and various levels of glycemic control and renal complications are unknown.

82 monoagonists to reduce body weight, enhance glycemic control and reverse hepatic steatosis in releva

83 the available evidence for GV as a marker of glycemic control and risk factor for diabetes complicati

84 on multiple levels, some involving improved glycemic control and some involving mechanisms outside g

85 treatment of type 2 diabetes (T2DM), improve glycemic control and stimulate satiety, leading to decre

86 te the longitudinal association between poor glycemic control and subsequent changes in retinal micro

87 ected to have consequential bearings on IAPP glycemic control and T2D pathology.

88 d tremendous potential to improve the normal glycemic control and to reduce the incidence of hypergly

89 Risk of insulin resistance, impaired glycemic control, and cardiovascular disease is excessiv

90 ular death increased with younger age, worse glycemic control, and greater severity of renal complica

91 dy-composition metrics, appetite, markers of glycemic control, and gut microbiota were measured at 2

92 produced a significant weight gain, restored glycemic control, and normalized measures of serum oxida

93 ps to lower risks of death depending on age, glycemic control, and renal complications.

94 lood pressure, cholesterol and blood lipids, glycemic control, and the use of aspirin) management for

95 overweight and obese patients with difficult glycemic control; and future research requirements are d

96 specialty journals for articles referring to glycemic control appearing between 2006 and 2015 and ide

97 diabetes and chronic hyperglycaemia, liberal glycemic control appears to attenuate glycemic variabili

98 with more physiological profiles and better glycemic control are needed, especially analogues that p

99 New methods to improve glycemic control are needed.

100 chanism or mechanisms by which leptin exerts glycemic control are unclear.

101 peptidase-4 inhibitors are commonly used for glycemic control as adjuncts to metformin, other oral an

102 Greater glycemic control as indicated by >/=1 CGM variable was a

103 iologically with diabetic complications, and glycemic control, as reflected by HbA1c reduction, resul

104 Outcomes were glycemic control assessed with use of measurements of Hb

105 en neighborhood supermarket gain or loss and glycemic control (assessed by glycated hemoglobin (HbA1c

106 imaging was obtained at the end of 1 year of glycemic control assessment.

107 ries for those with good, moderate, and poor glycemic control at baseline, while supermarket gain was

108 Adults appeared to benefit more for glycemic control at program completion (-0.28 [CI, -0.57

109 T1D, and the duration of diabetes, age, and glycemic control at the time of initial photography were

110 s for type 1 diabetes offer some benefit for glycemic control, at least at short-term follow-up, but

111 s and Children Hospital, 28 of whom had poor glycemic control (average glycated hemoglobin [HbA1c] >/

112 In patients with T1DM, poor glycemic control before CABG was associated with increas

113 Visual acuity, glycemic control, blood pressure, human immunodeficiency

114 uding anthropometric indices, blood factors, glycemic control, blood pressure, lipid tests, and liver

115 Additional analyses comprised glycemic control, BMI, HbA1c level, remission of comorbi

116 tidyl peptidase-4 (DPP-4) inhibitors provide glycemic control but also raised concerns about the risk

117 father had childhood type 1 diabetes in poor glycemic control, but lacked the mutation and had neithe

118 ell accepted that physical activity improves glycemic control, but the knowledge on underlying mechan

119 d glycated albumin are markers of short-term glycemic control, but their associations with cardiovasc

120 e neighborhood foreclosure rate could worsen glycemic control by activating stressors such as higher

121 These injectable analogs achieve robust glycemic control by increasing concentrations of "GLP-1

122 uclei, correlated inversely with measures of glycemic control, cerebrovascular burden and depression

123 to examine the effect of postoperative tight glycemic control compared with conventional blood glucos

124 lifestyle intervention results in equivalent glycemic control compared with standard care and, second

125 Tight glycemic control did not significantly alter the respons

126 conclude that patients with T1DM and stable glycemic control display enhanced platelet activation co

127 Furthermore, intensive glycemic control does not lead to improved patient-cente

128 mized clinical trials suggest that intensive glycemic control does not reduce major macrovascular eve

129 day-and-night closed-loop therapy maintained glycemic control during a high proportion of the time in

130 ia and diabetic ketoacidosis and with better glycemic control during the most recent year of therapy.

131 Most RCTs of intensive vs standard glycemic control excluded adults older than 80 years, us

132 e show that TLR3-deficient mice had enhanced glycemic control, facilitated by elevated insulin secret

133 y benefited from the effect of both wines on glycemic control (fasting plasma glucose, homeostatic mo

134 >/=9.0%) had the worst associated changes in glycemic control following either supermarket loss or ga

135 ogenitors to enhance the re-establishment of glycemic control following pancreatic islet transplantat

136 A) in the blood, are essential indicators of glycemic control for diabetes mellitus.

137 dministrations and improving the fidelity of glycemic control for insulin therapy.

138 an Hb, this could indicate a recent lapse in glycemic control for that patient.

139 that encourage an individualized approach to glycemic control for U.S. adults with type 2 diabetes re

140 lucose responsive, and they reinstate normal glycemic control for up to 248 d.

141 ementation had no effect on GLP-1 secretion, glycemic control, gastric emptying, body weight, or ener

142 mean 12-month costs were lower in the tight-glycemic-control group than in the conventional-glycemic

143 cemic-control group than in the conventional-glycemic-control group.

144 led to clinically important improvements in glycemic control (>/= 0.4% reduction in hemoglobin A1c [

145 Neither poor glycemic control (HbA1c >/=9.0%, adjusted HR: 1.04, 95%

146 ellitus who were not on insulin and had poor glycemic control (HbA1c >10%) had significantly higher l

147 s (P < 0.0001), insulin use (P = 0.002), and glycemic control (HbA1C < 7%) (P = 0.002) were used to d

148 Adequate glycemic control (HbA1c < 7%) was achieved in 66.7% of t

149 Long-term glycemic control (HbA1c <7%) was seen in 63% of patients

150 Among patients with relapse, 67% maintained glycemic control (HbA1c <7%).

151 27 age- and gender-matched subjects had good glycemic control (HbA1c <8%).

152 n Americans with diabetes mellitus varies by glycemic control, health status, and calendar year (befo

153 Clinical characteristics, glycemic control (hemoglobin A1c [HbA1c]), and presence

154 The other group showed no improvement in glycemic control (HOMA-IR mean change: -0.26; 95% CI: -0

155 Intensive glycemic control (IGC) targeting HbA1c fails to show an

156 l trials consistently suggest that intensive glycemic control immediately increases the risk of sever

157 Glycemic control improved overall, but total diabetes pr

158 Although intensive glycemic control improves outcomes in type 1 diabetes me

159 , blood pressure was below 140/90 mm Hg, and glycemic control in 85% up to 15 years after onset.

160 borhood supermarket presence did not benefit glycemic control in a substantive way.

161 cess risk of death according to the level of glycemic control in a Swedish population of patients wit

162 centives on glucose monitoring adherence and glycemic control in adolescents and young adults with ty

163 studies assessing the effect of metformin on glycemic control in adolescents with type 1 diabetes hav

164 mpounds work independent of insulin, improve glycemic control in all stages of diabetes mellitus in t

165 ing and modifying barriers impeding improved glycemic control in black persons with diabetes.

166 t it is unclear whether short period of poor glycemic control in children with T1D can cause evident

167 ticenter, randomized trial showed that tight glycemic control in critically ill children had no signi

168 has been suggested as an adjunct to improve glycemic control in critically ill patients.

169 Intensive insulin therapy for tight glycemic control in critically ill surgical patients has

170 ent effect was fully attributed to the prior glycemic control in DCCT (explained treatment effect: 10

171 erm trials of nuts on insulin resistance and glycemic control in diabetic individuals are inconsisten

172 We assessed whether poor glycemic control in Hp 1-1 carriers is more strongly ass

173 ing cells offers the potential for restoring glycemic control in individuals with diabetes.

174 ation that correlated with an improvement of glycemic control in men with T2DM.

175 blockade similarly improved inflammation and glycemic control in obese WT mice.

176 ere is substantial uncertainty about optimal glycemic control in older adults with type 2 diabetes me

177 important predictor of ischemic stroke than glycemic control in patients who have diabetes and AF.

178 l-forming, nonfermented fiber supplement, on glycemic control in patients who were being treated for

179 ontinuous positive airway pressure (CPAP) on glycemic control in patients with diabetes.

180 to diagnose type 2 diabetes (T2D) and assess glycemic control in patients with diabetes.

181 ffect of positive airway pressure therapy on glycemic control in patients with relatively well-contro

182 th more than 7 years of follow-up shows that glycemic control in patients with T1D after SIK/IAK tran

183 about the impact of tight versus less tight glycemic control in patients with type 2 diabetes mellit

184 fects of treating obstructive sleep apnea on glycemic control in patients with type 2 diabetes.

185 tide-1-based (GLP-1-based) therapies improve glycemic control in patients with type 2 diabetes.

186 hether a lifestyle intervention can maintain glycemic control in patients with type 2 diabetes.

187 abel subcutaneous semaglutide (secondary) on glycemic control in patients with type 2 diabetes.

188 d self-monitored glucose results in improved glycemic control in people with poorly controlled type 2

189 evelop new approaches to achieve near-normal glycemic control in real-world settings in people with t

190 e and health by examining annual measures of glycemic control in relation to local foreclosure activi

191 ery may achieve better and more long-lasting glycemic control in select patients with early-onset T2D

192 l therapy plus bariatric surgery resulted in glycemic control in significantly more patients than did

193 pharmacologic approaches for safer intensive glycemic control in T1DM.

194 subcutaneous adipocyte size predicted better glycemic control in T2D.

195 The incretin hormones improve glycemic control in T2DM by increasing insulin secretion

196 SIRT6 may be a viable strategy for improving glycemic control in T2DM.

197 as a clinical solution to improve long-term glycemic control in the context of diabetes.

198 and risk is reduced even when accounting for glycemic control in the form of glycated hemoglobin leve

199 ies of this potentially valuable therapy for glycemic control in the ICU are justified.

200 determine the impact of unknown diabetes on glycemic control in the ICU.

201 diabetes but have significant challenges in glycemic control in the ICU.

202 ovide a more complete picture of a patient's glycemic control in the months leading up to blood colle

203 ce that increased foreclosure rates worsened glycemic control in this continuously insured population

204 Poor glycemic control in Type 1 Diabetes (T1D) patients is st

205 Hypoglycemia limits optimal glycemic control in type 1 diabetes mellitus (T1DM), mak

206 Intensive glycemic control in type 2 diabetes (glycated hemoglobin

207 The challenges of achieving optimal glycemic control in type 2 diabetes highlight the need f

208 nt on GLP-1 secretion, gastric emptying, and glycemic control in type 2 diabetes.

209 , which may provide long-term improvement of glycemic control in type 2 diabetic patients.

210 f dietary intake with multiple indicators of glycemic control in youth with type 1 diabetes participa

211 g dietary intake variables with time-varying glycemic control indicators, controlling for age, height

212 However, hypoglycemia becomes an issue if glycemic control is accomplished with a sulfonylurea, a

213 The latter is not an issue if glycemic control is accomplished with drugs that do not

214 quality and macronutrient distribution with glycemic control is ambiguous.

215 Recent evidence suggests that glycemic control is associated with cognitive function i

216 Optimization of glycemic control is critical to reduce the number of dia

217 Long-term optimization of glycemic control is not achieved by a majority of indivi

218 most patients with type 1 diabetes, adequate glycemic control is not achieved with insulin therapy al

219 End points included narcotic requirements, glycemic control, islet function, quality of life (QOL),

220 and, among persons with diagnosed diabetes, glycemic control (<7.0% or <8.0%).

221 These findings suggest that glycemic control may be improved by increasing intake of

222 obesity and diabetes have become common and glycemic control may be poor.

223 Participants who had diabetes had poor glycemic control (mean [+/-SD] glycated hemoglobin level

224 nalyses of contemporary randomized trials of glycemic control measuring patient-important microvascul

225 m to benefit persons with suboptimal or poor glycemic control more than those with good control.

226 as all SC islet recipients failed to restore glycemic control (n = 0 of 10, P < 0.01, log-rank).

227 a-level attributes and according to baseline glycemic control (near normal, <6.5%; good, 6.5%-7.9%; m

228 A to VAD mice restores pancreatic VA levels, glycemic control, normal islet size distributions, beta-

229 gests that periodontal treatment may improve glycemic control of patients with DMt2 by eliminating pe

230 abetes management is the achievement of good glycemic control, of which glycated hemoglobin (HbA1c) r

231 Glycemic control often deteriorates during adolescence a

232 red twice daily via s.c. injection, improves glycemic control, often with associated weight reduction

233 We aimed to examine the impact of improved glycemic control on left ventricular (LV) function in th

234 beneficial effect of 6.5 years of intensive glycemic control on retinopathy in patients with type 1

235 ity after transplantation, but the effect of glycemic control on survival is unknown.We sought to det

236 ence reported no significant impact of tight glycemic control on the risk of dialysis/transplantation

237 was no apparent between-group difference in glycemic control or adverse events.

238 lure cannot be explained by their actions on glycemic control or as osmotic diuretics.

239 rsons than in white persons are due to worse glycemic control or racial differences in the glycation

240 s to assess the overall long-term functional glycemic control or the possibility of unrecognized diab

241 95% CI: 6.7-29.9, P < 0.001), higher rate of glycemic control (OR: 8.0, 95% CI: 4.2-15.2, P < 0.001)

242 Improvements in glycemic control over a 12-month period led to improveme

243 It is well known that glycemic control over time reduces microvascular and mac

244 ases in postprandial gut hormone secretions, glycemic control, pancreas morphology, and micronutrient

245 congenital heart disease, 15 underwent tight glycemic control postoperatively and 13 were treated con

246 To minimize adverse effects on glycemic control, prevention and management of general a

247 Primary outcomes were lipid and glycemic control profiles.

248 Poor glycemic control profoundly affects protein expression a

249 sought to determine the relationship between glycemic control (random blood glucose [RBG], fasting bl

250 betes mellitus (aged 54+/-10 years) and poor glycemic control received optimization of treatment for

251 erapy to insulin in T1DM, heralding improved glycemic control, reduced body weight and total daily in

252 Achieving glycemic control remains a challenge for patients with t

253 of type 1 diabetes (T1D) treatment; however, glycemic control remains a challenge.

254 These data suggest that optimizing glycemic control remains a substantive challenge requiri

255 Glycemic control, severe hypoglycemia, insulin requireme

256 During surgery, glycemic control should be implemented using blood gluco

257 Glycemic control significantly reduces the severity of t

258 od pressure control, lipid control, diabetic glycemic control, smoking cessation, and target body mas

259 Glycemic control strongly correlates with survival after

260 ontrol and some involving mechanisms outside glycemic control such as neurogenesis, inflammatory syst

261 active in rats, with an in vivo potency for glycemic control surpassing that of native GLP-1.

262 ith hyperglycemia did not benefit from tight glycemic control targeted to a blood glucose level of 80

263 In multicenter studies, tight glycemic control targeting a normal blood glucose level

264 LDL and duration of T1D, patients with poor glycemic control tended to have marginally wider retinal

265 inical trial showed that postoperative tight glycemic control (TGC) for children undergoing cardiac s

266 which combination treatment provides better glycemic control than metformin or SGLT2I monotherapy re

267 iabetes, oral semaglutide resulted in better glycemic control than placebo over 26 weeks.

268 tomated) insulin delivery can provide better glycemic control than sensor-augmented pump therapy, but

269 d with standard care resulted in a change in glycemic control that did not reach the criterion for eq

270 ht changes, on energy-metabolism metrics and glycemic control.The study was a randomized, controlled,

271 ere restricted to those with poorer baseline glycemic control, those with more severe sleep apnea, or

272 Interventions to improve glycemic control through early intensive treatment of di

273 n and glucagon confirms the role of GLP-1 in glycemic control through its action on pancreatic alpha

274 ion of whether or not to recommend intensive glycemic control to patients to minimize microvascular a

275 l policy statements about the value of tight glycemic control to reduce micro- and macrovascular comp

276 d, 632 with type 2 diabetes and insufficient glycemic control using diet and exercise alone or a stab

277 Glycemic control was assessed using glycohemoglobin data

278 Glycemic control was inadequate in 33.3% of LT recipient

279 rovided evidence that between 2007 and 2010, glycemic control was not associated with rates of comple

280 Dose-related worsening of glycemic control was noted in 14.5% of patients who rece

281 The improvement in glycemic control was observed without stimulation of the

282 high levels of obesity, diabetes was common, glycemic control was poor, and diabetes was associated w

283 patic interaction of Ad36E4ORF1 in enhancing glycemic control, we expressed E4ORF1 of Ad36 or Ad5 or

284 l changes in weight, lipids, and measures of glycemic control were observed during treatment with lur

285 l changes in weight, lipids, and measures of glycemic control were observed with lurasidone.

286 samples for analyzing HbA1c concentrations (glycemic control) were collected in the mobile examinati

287 or a DPP-4 inhibitor to metformin to improve glycemic control when a second oral therapy is considere

288 RYGB pigs displayed improved glycemic control, which was attributed to increases in b

289 sts that Ucn3 is a key contributor to stable glycemic control, whose reduction during diabetes aggrav

290 peutic strategies focusing solely on optimal glycemic control with currently available drugs or appro

291 diabetes mellitus who do not achieve optimal glycemic control with insulin monotherapy, is the additi

292 transplanted into the CP routinely restored glycemic control with modest delay and responded well to

293 lycemic medications are necessary to balance glycemic control with safety.

294 drugs for at least 12 hours to either tight glycemic control, with a target blood glucose range of 7

295 (4.0 to 7.0 mmol per liter), or conventional glycemic control, with a target level below 216 mg per d

296 igh-fat diet, Ocy-PPARgamma(-/-) mice retain glycemic control, with increased browning of the adipose

297 effects of the housing foreclosure crisis on glycemic control within a population of patients with di

298 Roux-en-Y gastric bypass (RYGB) improves glycemic control within days after surgery, and changes

299 o determine whether a " liberal" approach to glycemic control would reduce hypoglycemia and glycemic

300 rition management is critical to maintaining glycemic control, yet it is difficult to achieve due to